An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Launched by NOVARTIS PHARMACEUTICALS · Jul 23, 2013
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Active choroidal neovascularization (CNV)
- • Active macular edema (ME)
- • Rubeosis iridis/neovascular glaucoma.
- • Proliferative diabetic retinopathy requiring vitrectomy.
- Exclusion Criteria:
- • wet Age-related macular degeneration
- • pathologic myopia
- • pseudoxanthoma elasticum
- • diabetic macular edema
- • retinal vein occlusion
- • \< 18 years of age
- • History of hypersensitivity to ranibizumab
- • Use of any systemic anti-angiogenic drugs 3 months before inclusion
- • Women of child-bearing potential and Pregnant or nursing (lactating) women.
- • Active or suspected ocular infection
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Poitiers, , France
Paris, , France
Bordeaux, , France
Lille, , France
Montauban, , France
Toulouse, , France
Tours, , France
Nantes Cedex 1, , France
Lyon Cedex 04, , France
Vannes, , France
Strasbourg Cedex, , France
Amiens Cedex 1, , France
Creteil, , France
Paris Cedex 10, , France
Mulhouse Cedex, , France
Nice, , France
Angers, , France
Caen, , France
Grenoble, , France
Lyon, , France
Melun, , France
Montpellier, , France
Paris Cedex 19, , France
Paris, Cedex 12, , France
Rouen, , France
Saitnt Herblain, , France
St Priest En Jarez, , France
Saint Jean, , France
Bobigny Cedex, Seine Saint Denis, France
Ecully, , France
Mantes La Jolie, , France
Marseille Cedex 8, , France
Marseille, , France
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials